Tactile Systems Technology Inc (TCMD) Q1 2026 Earnings Call Transcript

Why It Matters

The earnings reveal a pivotal shift toward airway clearance products as the primary growth engine, while the lymphedema business faces transitional challenges that could affect near‑term profitability.

Key Takeaways

• Revenue flat at $61.3M, airway clearance up 22%
• Lymphedema sales fell 3% due to headcount gaps
• Gross margin improved to 74% after cost cuts
• Sales force expanding to 300 reps by year‑end
• AffloVest partnership drives airway clearance growth

Pulse Analysis

Tactile Systems Technology is leveraging its AffloVest platform to capture a growing share of the bronchiectasis market, a niche that is expanding as clinicians seek patient‑friendly, home‑based therapies. Prioritized placement agreements with the top ten durable medical equipment distributors have accelerated adoption, positioning AffloVest as a leading option behind the market leader. This momentum, combined with a 22% year‑over‑year increase in airway clearance revenue, underscores the strategic value of focusing on high‑margin, technology‑driven products that address unmet respiratory needs.

Conversely, the lymphedema segment is contending with a temporary dip caused by deliberate sales‑force restructuring and the rollout of a new Salesforce CRM system. While headcount reductions and learning‑curve effects suppressed revenue, the company’s disciplined approach to talent acquisition and territory realignment aims to restore coverage and improve efficiency. The CRM upgrade promises data‑driven insights and streamlined workflows that should boost rep productivity once the adoption curve flattens, ultimately supporting sustainable growth in the lymphedema market.

Financially, Tactile entered the quarter with $83.6 million in cash, a strong liquidity position despite a $10.7 million draw for stock repurchases. Adjusted EBITDA guidance of $32‑$34 million reflects ongoing investments in technology, including the Parachute e‑prescribing platform and AI‑enhanced order management tools, which are already driving a 25% e‑prescribing share for Nimbl orders. With operating expenses projected to rise 9‑11% and tariff exposure limited to under $5 million, the revised revenue outlook of $309‑$315 million signals confidence that airway clearance growth will offset lymphedema headwinds, offering investors a balanced risk‑reward profile.